Derived from proteins made by the body’s immune system, monoclonal antibodies are successful drugs used to treat millions of patients. The MRC/UCB Antibody Discovery Initiative offers academic researchers access to UCB’s high-tech antibody discovery platform. Andrew Popplewell, Head of Antibody Discovery and Engineering at UCB Celltech, explains how the initiative is geared to help promote collaborative research.
Image credit: Andrew Popplewell.
In the pharmaceutical and biotechnology industry today, collaboration and networking are all-important. And the value of tapping into academic knowledge, expertise, and talent is widely acknowledged.
Dr Pauline Williams leads global health research and development at GSK and recently became an MRC Council member. Here she tells us about mixing science with business, and the satisfaction of making a life-saving gel from an antiseptic mouthwash.
Dr Pauline Williams, GlaxoSmithKline. Image credit: GlaxoSmithKline
Career in brief:
- Medicine degree, University of Cardiff
- Clinical Pharmacology physician, Glaxo Phase I Unit
- Head of Academic Discovery Performance Unit, GSK
- Senior Vice President and Head of Global Health R&D, GSK
It was the rigour and excitement of early drug development that tempted me away from medicine. I did a stint at a Phase I Clinical Pharmacology Unit after my medical training – and following that I was enticed by an offer to join Glaxo (now GSK) where I’ve worked ever since. My first role was a full immersion in the design, conduct and reporting of experimental medicine studies which has stood me in good stead throughout my career.